Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
50.39
-0.18 (-0.36%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Travere Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Travere Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $75.21. The average 1-year stock price forecast is 49.26% higher than the current stock price, while the lowest is $62 (+23.04%) and the highest is $90 (+78.61%).
Price Target: $75.21 (+49.26%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 12 | 12 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $70 | Buy | Reiterates | $70 | +38.92% | Oct 28, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $71 | Buy | Reiterates | $71 | +40.90% | Oct 28, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $67 | Buy | Reiterates | $67 | +32.96% | Oct 26, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $68 | Buy | Maintains | $68 | +34.95% | Oct 21, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $80 | Buy | Maintains | $80 | +58.76% | Oct 15, 2026 |
Financial Forecast
Revenue This Year
723.77M
from 490.73M
Increased by 47.49%
Revenue Next Year
1.08B
from 723.77M
Increased by 48.73%
EPS This Year
1.45
from 0.91
Increased by 59.10%
EPS Next Year
5.39
from 1.45
Increased by 272.37%
EPS and Forward PE are based on non-GAAP adjusted numbers.